Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuantum Data Regulatory News (MAST)

  • There is currently no data for MAST

Hindlip Construction Progress Update

20 Aug 2025 07:00

RNS Number : 9746V
Mast Energy Developments PLC
20 August 2025
 

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

LEI :213800HFVHGJ9YGO9F71

Share code on the LSE: MAST

ISIN: GB00BNG90H86

("MED" or "the Company")

 

Dated: 20 August 2025

 

Mast Energy Developments PLC

("MED" or the "Company")

 

Hindlip Construction Progress Update

 

Mast Energy Developments PLC is pleased to announce, further to its RNS announcement dated 6 May 2025, a construction progress update regarding its Hindlip 7.5 MW flexible generation power site which is fully funded in partnership with Powertree, the highlights and details of which are outlined below.

 

Hindlip Construction Progress Highlights:

· Site property's long-term leasehold option exercised and the long-term leasehold agreement exchanged and completed;

· Grid connection >5 MW Gate 2 protection application submitted and approved;

· Grid connection for c. 7.5 MW secured and majority of construction costs already paid;

· RFP submitted to industry-leading EPC firms, and following careful review of associated EPC proposals, MTU (Rolls Royce) engines selected as the best option for this site;

· Contract for new engines executed and order placed; and

· Site full construction works (including inter alia civils, LV and HV electricals, and grid- and gas connection) planned to commence in September 2025, with Commercial Operations Date ("COD") expected in Q2 2026.

 

Pieter Krügel, MED CEO, commented"We are very pleased with the construction progress at Hindlip, with construction on track to be completed and COD expected in Q2 2026. It is a pleasure working with a partner of the calibre of Powertree, which not only brings investment capital to the table, but also a wealth of industry experience."

 

"The Hindlip site's already secured Capacity Market T-4 15-year contract with a cumulative guaranteed gross profit income value of c. £6.3m (before inflation increases) as previously announced, plus Embedded Benefits income, and PPA merchant trading income following COD make the site a very attractive investment. This along with other key elements including inter alia these types of flexgen sites being a critical part of the UK's energy security policy, fits perfectly into MED's business model and strategy to build a portfolio of 300+ MW."

 

"We are looking forward to updating the market with further positive progress and developments over the coming weeks."

 

Stay up to date with MED's latest news and updates by joining our emailing list and social media channels, as follows:

 

MED general enquiries - https://www.med.energy/contact

MED email alerts - https://www.med.energy/rnsannoucements-1

MED LinkedIn page - https://uk.linkedin.com/company/mast-energy-developments-plc

MED X (formerly Twitter) handle - @mastplc

 

 

ENDS

 

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information please visit www.med.energy or contact:

Pieter Krügel

info@med.energy

Mast Energy

Developments PLC

CEO

Guy Wheatley, CFA

+44 (0)74 9398 9014

Fortified Securities

Corporate Broker

Jon Belliss

+44 (0)20 7399 9425

Novum Securities

Corporate Broker

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBLGDICSBDGUC
Date   Source Headline
11th Feb 20257:00 amRNSRecord High January Revenues
27th Jan 20257:00 amRNSNew Website Launch
13th Jan 20257:00 amRNSRecord High Sales Price Achieved
19th Dec 20247:00 amRNSCompany Update
3rd Dec 20247:00 amRNSCompany Update
22nd Nov 20247:00 amRNSOperating & Corporate Update
14th Oct 202412:30 pmRNSHolding(s) in Company
10th Oct 202412:20 pmRNSHolding(s) in Company
8th Oct 202412:30 pmRNSHolding(s) in Company
7th Oct 20247:00 amRNSRecord High September Revenues
1st Oct 20248:00 amRNSShares Lock-in Agreement & Pyebridge Update
12th Sep 20247:00 amRNSPyebridge Revenue Updates
30th Aug 20247:00 amRNSHalf-year Report
20th Aug 20247:00 amRNSBusiness Update
13th Aug 202412:30 pmRNSTR-1 Notification
8th Aug 20244:30 pmRNSTR-1 Notification
7th Aug 20247:00 amRNSPyebridge Revenue Update re Refurbished Genset
31st Jul 20243:00 pmRNSTR-1 Notification
30th Jul 20247:00 amRNSTR1 Notification
1st Jul 20247:00 amRNSRevenue Generation & Potential Acquisition
13th Jun 20247:00 amRNSBusiness Update
5th Jun 20241:22 pmRNSHolding(s) in Company
30th May 20242:00 pmRNSResult of AGM
29th May 20249:11 amRNSHolding(s) in Company
23rd May 20243:55 pmRNSCapitalisation of Loan Update
21st May 20247:00 amRNSBusiness Update
9th May 202410:45 amRNSHolding(s) in Company
8th May 20247:00 amRNSNotice of AGM
7th May 20247:00 amRNSUpdate, Loan Capitalisation & Equity Issue
30th Apr 20247:00 amRNSResults for the year ended 31 December 2023
26th Apr 20247:00 amRNSBusiness Update
23rd Apr 20242:30 pmRNSHolding(s) in Company TR 1
11th Apr 20247:00 amRNSBusiness Update
7th Mar 20248:06 amRNSQ1 2024 Corporate Presentation
4th Mar 202410:45 amRNSHolding(s) in Company
28th Feb 20247:00 amRNSFunding Partner, Agreement & Proventure Terminated
20th Feb 20241:00 pmRNSTR-1: Standard form notification of major holdings
5th Feb 20241:55 pmRNSTR-1: Standard form notification of major holdings
24th Jan 20243:45 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSMED Binding JVA Progress Update
2nd Jan 20247:00 amRNSMED Binding JVA Completion Update
22nd Dec 20237:00 amRNSMED Binding JVA Completion Update
15th Dec 20237:00 amRNSDirector Loan & PDMR Share Sale
11th Dec 20237:52 amRNSMED Binding JVA Update
11th Dec 20237:00 amRNSMED Binding JVA Completion Update
5th Dec 20234:30 pmRNSHolding(s) in Company
1st Dec 20237:00 amRNSMED Binding JVA Completion Update
15th Nov 20233:31 pmRNSDirector/PDMR Shareholding
13th Nov 20237:00 amRNSMED Binding JVA Interim Payment Update
26th Oct 202310:54 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.